Why the study?
Do immunomodulating agents improve survival and reduce myocardial lesions in murine models of viral myocarditis?
Population
Murine models of viral myocarditis induced by the encephalomyocarditis (EMC) virus
Design
Preclinical
Authors
Loading...
Supports further study of immunomodulators in viral myocarditis; should not yet alter clinical management.
Do immunomodulating agents improve survival and reduce myocardial lesions in murine models of viral myocarditis?
Immunomodulating agents such as anti-TNF-alpha antibodies, vesnarinone, and angiotensin II antagonists show promise in treating and preventing viral myocarditis in murine models.
Matsumori et al. (1995) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: